Literature DB >> 30655076

Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population.

Tejas Suresh1, Janaki Sharma2, Sanjay Goel2, Evan Kovac3, Qi Gao4, Benjamin Gartrell2.   

Abstract

BACKGROUND: In the United States, the prostate cancer (PCa) incidence and death rate has been greater in non-Hispanic black (NHB) men than in non-Hispanic white (NHW) men and slightly lower in Hispanic men than in NHW men. We compared the sociodemographic and baseline prognostic factors at the diagnosis of PCa in different races/ethnicities at a large, academic center serving an ethnically diverse population.
METHODS: The Montefiore Medical Center Cancer Registry was used to generate a comprehensive list of all patients with PCa diagnosed from 2004 to 2014. The clinical Looking Glass (a proprietary searchable database of patient information) and individual patient medical record review were used to obtain data, including age at diagnosis, socioeconomic status (SES), clinical Gleason score, clinical stage, and prostate-specific antigen level at diagnosis. The patients were classified by self-identified race/ethnicity as Hispanic, NHB, NHW, or other. The χ2 test was used for categorical variables, and analysis of variance or the Kruskal-Wallis test was used for continuous variables.
RESULTS: We identified 2352 patients with newly diagnosed PCa during the study period, including 778 Hispanic, 1046 NHB, 486 NHW, and 42 other. The NHW men were significantly older at diagnosis (Hispanic, 63.2 years; NHB, 63.4 years; NHW, 67 years; other, 63.0 years; P < .0001). The mean SES for the Hispanic and NHB men was significantly lower (SES below average: Hispanic, 92.8%; NHB, 91.3%; NHW, 56.6%; other, 75%; P < .0001). The Gleason score at diagnosis differed among these race groups (Gleason score ≤6 PCa: Hispanic, 42.8%; NHB, 39.1%; NHW, 52.2%; other, 50%; Gleason score 8-10: Hispanic, 15.8%; NHB, 17.6%; NHW, 14.3%; other, 16.7%; P = .0005). The proportion of men with metastatic disease at diagnosis also differed significantly among the groups (Hispanic, 7.5%; NHB, 9.0%; NHW, 4.3%; other, 9.5%; P = .0139). Using pairwise comparisons, the odds ratio for a higher Gleason score at presentation between NHB and NHW was 1.592 (P < .001) and was 1.378 for Hispanic versus NHW (P = .0200). The pairwise comparison for metastatic disease at diagnosis showed an odds ratio of 2.186 for NHB versus NHW (P = .0087). After adjusting for SES, the odds ratio for a higher Gleason score comparing NHB and NHW was 1.55 (P = .001). Although the odds of metastatic disease were greater in Hispanic men than in NHW men (odds ratio, 1.784), the differences were not statistically significant (P = .1197).
CONCLUSIONS: At our center, the clinical features of men from different racial groups differed significantly at the time of newly diagnosed PCa. Differences included age at diagnosis, SES, Gleason score, and proportion with metastatic disease. Our pairwise comparisons between different ethnic groups suggested that PCa in Hispanic men might be more similar to that in NHB than to that in NHW patients and are generally more aggressive at diagnosis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  African-American; Ethnic minority; Hispanic; Socioeconomic

Mesh:

Year:  2018        PMID: 30655076     DOI: 10.1016/j.clgc.2018.12.003

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  6 in total

1.  Clinicopathological features, treatment and outcome of Omani patients with localised prostate cancer.

Authors:  Shiyam Kumar; Ikram A Burney; Namrata Satyapal; Joseph Kunju; Mohamed Salim Al-Marhoon; Khurrum Mutahir Siddiqui
Journal:  Arab J Urol       Date:  2020-07-06

2.  Racial/ethnic disparities in patient experiences with care and Gleason score at diagnosis of prostate cancer: a SEER-CAHPS study.

Authors:  Stephanie Navarro; Xiaohui Hu; Aaron Mejia; Carol Y Ochoa; Trevor A Pickering; Leslie Ballas; Albert J Farias
Journal:  Cancer Causes Control       Date:  2022-01-15       Impact factor: 2.506

3.  The impact of surgical downgrading on prostate cancer recurrence: systematic review and analysis of a multiethnic population.

Authors:  Denzel Zhu; William Shyr; Michelle Toker; Ethan Fram; Jinrong Cheng; Evan Z Kovac; Ilir Agalliu; Ahmed Aboumohamed; Kara L Watts
Journal:  World J Urol       Date:  2021-11-30       Impact factor: 4.226

4.  Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions.

Authors:  Nishi Karunasinghe; Tsion Zewdu Minas; Bo-Ying Bao; Arier Lee; Alice Wang; Shuotun Zhu; Jonathan Masters; Megan Goudie; Shu-Pin Huang; Frank J Jenkins; Lynnette R Ferguson
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

5.  Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients.

Authors:  Benedikt Hoeh; Jan L Hohenhorst; Rocco Flammia; Benedikt Horlemann; Gabriele Sorce; Francesco Chierigo; Zhe Tian; Fred Saad; Markus Graefen; Michele Gallucci; Alberto Briganti; Carlo Terrone; Shahrokh F Shariat; Luis A Kluth; Andreas Becker; Felix K H Chun; Pierre I Karakiewicz
Journal:  Int Urol Nephrol       Date:  2021-11-16       Impact factor: 2.370

6.  Prospective evaluation of PI-RADS v2 and quantitative MRI for clinically significant prostate cancer detection in Indian men - East meets West.

Authors:  Vijay Kubihal; Vikas Kundra; Vivek Lanka; Sanjay Sharma; Prasenjit Das; Rishi Nayyar; Chandan J Das
Journal:  Arab J Urol       Date:  2022-05-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.